A Phase II, Randomized, Open-Label, Multi-arm Study of TAS-115 for Castration-Resistant Prostate Cancer Patients With Bone Metastases

CONCLUSION: TAS-115 appears to demonstrate anti-tumor activity and acceptable tolerability in CRPC patients with bone metastases.PMID:34493431 | DOI:10.1016/j.clgc.2021.07.013
Source: Clinical Breast Cancer - Category: Cancer & Oncology Authors: Source Type: research